Rheumatoid Arthritis Treatment Market

Global Market Study on Rheumatoid Arthritis Treatment: Combination Treatment to Gain Immense Popularity Over Coming Years

  • May-2021
  • PMRREP22555
  • 295 Pages
  • Healthcare
  • PPT, PDF, WORD, EXCEL

About the Report

Rheumatoid arthritis is related with the immune system, and leads to inflammation of the joints in the body. As it progresses, the disease affects the muscles, fibrous tissues, tendons, and connective tissues as well. Rheumatoid arthritis affects performance of day-to-day activities, including household tasks and work, and also results in mortality. Some determinations suggests that individuals who smoke frequently are at high danger of getting affected with rheumatoid arthritis.

Globally, leading companies are maintaining their market position by acquiring companies who are facing a large number of product recalls. Also, favourable reimbursement policies and increasing healthcare expenditure are some other factors driving market expansion.

A latest revised report by Persistence Market Research details the trends in 20+ high growth markets, along with the impact the COVID-19 pandemic has had on the healthcare industry in general, and on the demand for rheumatoid arthritis treatment in particular.

This edition (2021-2031) brings readers up-to-date with key market developments, providing analysis on how manufacturers and other stakeholders are reacting to change. The study also provides a competitive landscape section, and readers will get to know the key strategies of established players as well as new entrants.

Find Out More about the Report Coverage

Companies

  • Sanofi SA
  • Pfizer Inc.
  • AbbVie Inc.
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • F. Hoffman-La Roche AG
  • Teva Pharmaceuticals, Inc.
  • Cipla, Inc.
  • Dr. Reddy’s Laboratories
  • Sun Pharmaceutical Industries Ltd.
  • Roxane Laboratories Inc,
  • Amneal Pharmaceuticals LLC.
  • Sobi Inc.
  • Norbrook Laboratories Ltd.

What is the Future Demand Scenario for Rheumatoid Arthritis Treatment in Comparison to Historic Trends?

Increasing prevalence of arthritis and other joint problems is fuelling demand for rheumatoid arthritis treatment. Because of the shift toward unhealthy lifestyle, increasing metabolic diseases & age, family history with joint diseases, and increased obesity rheumatoid arthritis is on the rise. Manufacturers are focusing on partnerships with other players to enhance their position in this space.

According to Persistence Market Research’s analysis, the rheumatoid arthritis treatment market is projected to progress at a CAGR of around 6% from 2021 to 2031.

Customize this Report

Explore Intelligence Tailored to Your Business Goals.

How are Flourishing Combination Treatment and Dual Inhibitors Aiding Market Expansion?

Different combinations of biologics to treat RA are expected to achieve more complete control of joint inflammation and destruction. Even though the first trial on combination therapy with anakinra and abatacept was shown to increase chances of infection, TNF inhibitors and interlukin-17 inhibitors such as secukinumab seem to be more a promising combination therapy.

Recent pre-clinical investigations have shown that combination is significantly capable of reducing joint pathology in the murine experimental arthritis model. Hence, a future combination of TNF inhibitors with an anti-IL-17 antibody seems plausible. Moreover, new era of bi-specific antibodies is expected to push market growth over the forecast period.

  • In November 2019, Pfizer announced that FDA approved its biosimilar, abrilada™ (adalimumab-afzb) for multiple inflammatory conditions.

  • In 2020, Mylan announced that FDA has approved Hulio (adalimumab-fkjp, Mylan/Fujifilm Kyowa Kirin), a biosimilar to Humira (adalimumab, AbbVie). It is a TNF inhibitor intended to treat patients with rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn’s disease, ulcerative colitis, and plaque psoriasis.

Successful launch of these combinations would drive the global market for rheumatoid arthritis treatment. With further technical developments, the market for combination treatments is expected to flourish.

Market Research Methodology - Perfected through Years of Diligence

A key factor for our unrivaled market research accuracy is our expert- and data-driven research methodologies. We combine an eclectic mix of experience, analytics, machine learning, and data science to develop research methodologies that result in a multi-dimensional, yet realistic analysis of a market.

Get actionable insights on Ship Repair And Maintenance Services Market

Will Strengthening of Pipeline Drive Demand for Rheumatoid Arthritis Treatment?

Novel technologies to enhance the therapeutic potential of antibodies such as bi-specific antibodies and novel targets such as JAK enzymes have opened new opportunities for providers of rheumatoid arthritis treatment.

Majority of key players have combination DMARD therapies in their pipelines, and a majority of these programs involve investigation of new/existing biologic therapies with adalimumab-the highest selling anti-rheumatic drug across the globe.

Rheumatoid Arthritis Treatment Market

Explore Persistence Market Research’s expertise in promulgation of the business !

Country-wise Insights

Will the U.S. Offer Lucrative Opportunities to Rheumatoid Arthritis Treatment Industry Players?

The United States is predicted to remain one of the most attractive markets during the forecast period, according to Persistence Market Research. The country’s high healthcare spending is one of the main factors supporting market growth. Overall healthcare spending grew at a faster rate of around 4.6 percent in 2019 than overall economic growth of 4 percent in the United States, according to CMS Office of Actuary estimates.

The United States is estimated to encounter rapid development during the estimated period because of active support from both, the private sector and the government, technological advancements, rising number of research & development activities, and fast increasing awareness regarding rheumatoid arthritis.

In addition, increase and improvements in well-developed healthcare infrastructure will be a vital part in the development of the market in the country.

Why is Demand for Rheumatoid Arthritis Treatment Increasing in the U.K.?

The U.K. healthcare system possesses a well-developed infrastructure, largely supported by the government. It is perhaps the best healthcare systemin the world. It is not surprising that the U.K. has the most elevated level of expenditure in Europe. The U.K. is recognized as a main market, and this position is probably going to remain through the forecast years.

Moreover, rising research activities, presence of several major players, and increasing pipeline drugs are producing several opportunities for rheumatoid arthritis treatment industry stakeholders across the country.

Why is Innovation Key to Succeed in the German Pharmaceutical Market?

Germany is one of the world’s top most manufacturers of pharmaceuticals. Manufacturers in the country have a competitive advantage as they are developing products and leveraging cutting-edge research to address unmet challenges.

Additionally, they are constantly investing in order to expand their operations, which is resulting in a more promising pipeline. Moreover, companies are prioritizing areas with high unmet needs and working toward developing innovative products in these areas.

  • For instance, in 2020, Bayer AG announced its plan to expand its Beijing supply center with the construction of a new production and supply facility at Beijing Economic-Technological Development, with an investment of around US$ 59 million.

How are Government Initiatives Boosting Rheumatoid Arthritis Treatment in India?

Rising government initiatives to give quality and affordable healthcare are anticipated to supplement development of India's market. In addition, India is considered as one of the top countries of infections in the world, increasing the requirement for rheumatoid arthritis treatment around the country.

Rising patient pool because of increase in population, lifestyle changes, and emergence of new diseases is also driving interest in biopharmaceuticals. Also, Indian producers are expecting to extend their businesses through consolidations and acquisitions with different organizations.

  • For instance, in April 2019, Cipla Ltd. acquired 30% Stake in South African's Brandmed for Business Expansion. The acquisition was carried out to pair the company’s strengths with Brandmed’s innovative, patient-centric approach to healthcare, which will enhance Cipla Medpro’s portfolio.

Category-wise Insights

Why is Disease Modifying Anti-rheumatic Drugs (DMARDs) the Most Preferred Therapy for Rheumatoid Arthritis?

Disease modifying anti-rheumatic drugs (DMARDs) will continue accounting for the highest share among the therapies, through the forecast period. According to Persistence Market Research, the segment held slightly more than 75% market share, in terms of therapy, in 2020.

DMARDs are observed as the most effective treatment across regions. Major factors leading to increased demand for DMARDs are increasing awareness associated with their, rise in occurrence of rheumatoid arthritis, increase in overweight and obese population across the world, and rise in use of DMARDs as a first-choice therapy for rheumatoid arthritis.

Competitive Landscape

Companies operating in the market are aiming at strategic collaborations and acquisitions with other manufacturers to expand their product manufacturing and address the demand of an expanding patient pool.

  • For instance, in 2020, Pfizer and Lilly went into a collaboration agreement to jointly develop and globally commercialize tanezumab for the treatment of osteoarthritis pain and cancer pain, under which the companies equally share ongoing development costs.

  • In February 2021, Pfizer and Imcyse, a Belgium-based clinical-stage biopharmaceutical company, announced that they have entered into a research collaboration and license agreement for the potential treatment of rheumatoid arthritis (RA) via Imcyse’s RA program based on its Imotope technology.

Manufacturers are also focusing on the expansion of their product portfolios by launching new technologically advanced products and by receiving approval from different government bodies.

  • For instance, in August 2019, AbbVie announced that the U.S. Food and Drug Administration (FDA) has approved RINVOQ™ (upadacitinib), a 15 mg, once-daily oral Janus kinase (JAK) inhibitor, for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate (MTX-IR).

  • In November 2020, the U.S. Food and Drug Administration approved the emergency use of Eli Lilly’s arthritis drug baricitinib, in combination with Gilead Sciences’ remdesivir, to treat COVID-19 patients.

Some of the leading companies operating in the market are:

  • Sanofi S.A.
  • Pfizer Inc.
  • Johnson & Johnson
  • AbbVie Inc.
  • Eli Lilly & Company
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • F. Hoffman-La Roche AG
  • Cipla, Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Sobi Inc.
  • Novartis AG ( Sandoz)
  • UCB S.A.

*The list is not exhaustive, and only for representational purposes. Full competitive intelligence with SWOT analysis available in the report.

Scope of Report

Attribute

Details

Forecast Period

2021-2031

Historical Data Available for

2016-2020

Market Analysis

USD Million for Value

Key Regions Covered

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • The Middle East & Africa

Key Countries Covered

  • US
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • China
  • Japan
  • South Korea
  • India
  • Thailand
  • Malaysia
  • Indonesia
  • Australia
  • New Zealand
  • GCC Countries
  • Turkey
  • Northern Africa
  • South Africa

Key Segments Covered

  • Therapy
  • Distribution Channel
  • Region

Key Companies Profiled

  • Sanofi S.A.
  • Pfizer Inc.
  • Johnson & Johnson
  • AbbVie Inc.
  • Eli Lilly & Company
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • F. Hoffman-La Roche AG
  • Cipla, Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Sobi Inc.
  • Novartis AG ( Sandoz)
  • UCB S.A.

Report Coverage

  • Market Forecast
  • Company Share Analysis
  • Competition Intelligence
  • DROT Analysis
  • Market Dynamics and Challenges
  • Strategic Growth Initiatives

Customization & Pricing

Available upon Request

Market by Segmentation by Category

By Therapy

  • Symptomatic Treatment
  • Intermediate Corticosteroid Therapies
  • Stem Cell Therapy/ Cell Therapy
  • Disease Modifying Anti-rheumatic Drug (DMARD)
    • Conventional DMARDs
    • Biological DMARDs

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores

By Region

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East and Africa (MEA)

Key Questions Answered in Report

  • Which is the most lucrative market for rheumatoid arthritis treatment?

    The U.S. currently leads the global market for rheumatoid arthritis treatment. Sales in the U.S will be more than 40% of total demand in the world over the forecast period.

  • Which is the most preferred rheumatoid arthritis therapy?

    DMARDs are highly sought-after in every market. Demand for DMARDs is expected to remain high in the near future, especially due to increasing awareness associated with their utilization.

  • Which distribution channel accounts for maximum revenue?

    Hospital pharmacies continue to remain the leading sales channel for rheumatoid arthritis drugs. Utilization of recommended therapies in clinics and hospitals assist with overseeing a prescribed drug conveyance by a doctor securely, is one of the major factor driving the hospital pharmacies segment.

  • Which are some of the leading companies offering rheumatoid arthritis treatment equipment?

    Some of the leading companies offering rheumatoid arthritis treatment equipment are Sanofi S.A., Pfizer Inc., Johnson & Johnson, AbbVie Inc., Eli Lilly & Company, Amgen Inc., and Bristol-Myers Squibb Company.

Enquiry before Buying

  • Is this research conducted by Persistence Market Research?

    Yes, the research has been conducted by expert analysts of Persistence Market Research, through a combination of primary research and secondary research. To know more about how the research was conducted, you can speak to a research analyst.

  • What research methodology is followed by Persistence Market Research?

    Persistence Market Research follows a methodology that encompasses demand-side assessment of the market, and triangulates the same through supply-side analysis. This methodology is based on the use of standard market structure, methods, and definitions. Request a detailed methodology.

  • Who are the respondents for primary research?

    Persistence Market Research speaks to stakeholders across the spectrum, including C-level executives, distributors, product manufacturers, and industry experts. For a full list of primary respondents, please reach out to us.

  • What are the sources of secondary research?

    Persistence Market Research conducts extensive secondary research through proprietary databases, paid databases, and information available in the public domain. We refer to industry associations, company press releases, annual reports, investor presentations, and research papers. More information about desk research is available upon request.

  • Is a sample of this report available for evaluation?

    Yes, you can request a sample, and it will be sent to you through an email.

  • How can I buy this report?

    Persistence Market Research provides a secure online payment system to buy reports seamlessly. You can buy the report securely and safely.

Media Release

Our Clients

Our Clients